← Human Trials & Peer-Reviewed Studies
Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology.
Plain-language guide to PMID 23208461 (2013): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).
Key Facts
- PMID
- 23208461
- Journal
- Archives of gynecology and obstetrics
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Eftekhar M et al. (4 authors)
- DOI
- 10.1007/s00404-012-2655-1
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin), published as a randomized controlled trial.
Growth hormone augments the effect of gonadotropin on granulosa and theca cells, and plays an essential role in ovarian function, including follicular development, estrogen synthesis and oocyte maturation.
The aim of this study was to assess IVF-ET cycle outcome after the addition of growth hormone in antagonist protocol in poor responders.
Who Took Part
PubMed indexes the participants as adults, women only.
Eighty-two poor responder patients selected for ART enrolled the study and were randomly divided into two groups.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Group I (GH/HMG/GnRHant group, n = 40) received growth hormone/gonadotropin/GnRH antagonist protocol and group II (HMG/GnRHant group, n = 42) received gonadotropin/GnRH antagonist protocol.
What Was Measured
PubMed files the paper under topics including Chorionic Gonadotropin, Chorionic Gonadotropin, beta Subunit, Human, Embryo Transfer, Estradiol, Fertilization in Vitro, Gonadotropin-Releasing Hormone and Growth Hormone.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2013 (Archives of gynecology and obstetrics), a journal based in Germany.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- hCG (human chorionic gonadotropin) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.